BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...GDF15’s immunosuppressant function to enable immune cell infiltration to tumors By stephen hansen, Associate Editor CatalYm...
...that GDF15 has a second function as an immune tolerance factor independent of its metabolic effect.CatalYm GmbH...
...Intercellular adhesion molecule-1LFA-1 (CD11a-CD18)PD-1 (PDCD1; CD279) – Programmed cell death 1 Stephen Hansen Catalym GmbH Growth differentiation factor 15 (GDF15) CatalYm...
BioCentury | Nov 3, 2017
Financial News

BioGeneration closes Ventures Fund III at EUR82M

...The VC has already invested in five companies from the new fund: German immuno-oncology play Catalym GmbH...
BioCentury | Oct 31, 2017
Financial News

BioGeneration closes third fund

...The VC has already invested in five companies from the new fund: German immuno-oncology play Catalym GmbH...
BioCentury | Jul 5, 2017
Financial News

BioGeneration raises €66M for third fund

...in the Benelux countries and Germany. It has already made four investments, including immunotherapy company Catalym GmbH...
BioCentury | Jun 27, 2017
Financial News

BioGeneration's third fund tops target

...in the Benelux countries and Germany. It has already made four investments, including immunotherapy company Catalym GmbH...
Items per page:
1 - 5 of 5
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

...GDF15’s immunosuppressant function to enable immune cell infiltration to tumors By stephen hansen, Associate Editor CatalYm...
...that GDF15 has a second function as an immune tolerance factor independent of its metabolic effect.CatalYm GmbH...
...Intercellular adhesion molecule-1LFA-1 (CD11a-CD18)PD-1 (PDCD1; CD279) – Programmed cell death 1 Stephen Hansen Catalym GmbH Growth differentiation factor 15 (GDF15) CatalYm...
BioCentury | Nov 3, 2017
Financial News

BioGeneration closes Ventures Fund III at EUR82M

...The VC has already invested in five companies from the new fund: German immuno-oncology play Catalym GmbH...
BioCentury | Oct 31, 2017
Financial News

BioGeneration closes third fund

...The VC has already invested in five companies from the new fund: German immuno-oncology play Catalym GmbH...
BioCentury | Jul 5, 2017
Financial News

BioGeneration raises €66M for third fund

...in the Benelux countries and Germany. It has already made four investments, including immunotherapy company Catalym GmbH...
BioCentury | Jun 27, 2017
Financial News

BioGeneration's third fund tops target

...in the Benelux countries and Germany. It has already made four investments, including immunotherapy company Catalym GmbH...
Items per page:
1 - 5 of 5